IP Library Granted Patent US 9,855,376
Granted Patent B2
US 9,855,376 · App. 14/808,540 · Granted Jan 2, 2018

Power scaling

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,855,376
App. No.
14/808,540
Granted
Jan 2, 2018
Kind
B2
Abstract

Disclosed are systems and methods for measuring and calculating parameters to control and monitor a power transfer in an implanted medical device, including operating the device in a plurality of scalable power modes and/or coupling modes. The system may shift between or among power and/or coupling modes based on input such as data received over system communication lines, programmable timers, or electrical loading information. The system may also shift between or among power and/or coupling modes based on calculated amounts of coupling, levels of detected heat flux, and/or amounts of estimated temperature changes.

Claims (28)

1. A method of monitoring and controlling power transfer between a primary assembly and a secondary assembly of a transcutaneous energy transfer system used in an implanted cardiac medical device, comprising:

operating the transcutaneous energy transfer system in a first power mode, the first power mode being one of a plurality of scalable power modes;

determining if the transcutaneous energy transfer system is to be switched to a second power mode, the second power mode being one of the plurality of scalable power modes; and

switching from the first power mode to the second power mode by controlling power transfer between the primary assembly and secondary assembly.

2. The method of claim 1 , wherein the primary assembly includes a power transmitting system including a primary coil.

3. The method of claim 1 , wherein the secondary assembly includes a power receiving system including a secondary coil.

4. The method of claim 1 , wherein the scalable power modes includes a set of power delivery ranges defined from a low power range to a high power range.

5. The method of claim 4 , wherein the set of power delivery ranges includes at least one intermediate power delivery range between the low power range and the high power range.

6. The method of claim 1 , wherein determining if the transcutaneous energy transfer system is to be switched includes determining if a request to complete an initial powerup sequence is received.

7. The method of claim 1 , wherein determining if the transcutaneous energy transfer system is to be switched includes determining if a request to verify the correct secondary assembly is received.

8. The method of claim 1 , wherein determining if the transcutaneous energy transfer system is to be switched includes determining if a request for increased or decreased power is received.

9. The method of claim 8 , wherein the variable transformer has a plurality of discrete states each corresponding to one of the scalable power modes.

10. The method of claim 1 , wherein determining if the transcutaneous energy transfer system is to be switched includes determining if a request to enter a fault mode is received.

11. The method of claim 1 , wherein determining if the transcutaneous energy transfer system is to be switched includes determining if a predetermined time has elapsed since power up.

12. The method of claim 1 , wherein determining if the transcutaneous energy transfer system is to be switched includes determining if a predetermined time has elapsed since a fault condition was detected.

13. The method of claim 1 , wherein determining if the transcutaneous energy transfer system is to be switched includes determining if a predetermined time has elapsed since a change in a coupling coefficient occurred.

14. The method of claim 1 , wherein determining if the transcutaneous energy transfer system is to be switched includes determining if a fault condition is detected.

15. The method of claim 14 , wherein the fault condition includes excess current being drawn by the secondary assembly.

16. The method of claim 1 , wherein determining if the transcutaneous energy transfer system is to be switched includes determining if a change in a coupling coefficient is detected.

17. The method of claim 1 , wherein determining if the transcutaneous energy transfer system is to be switched includes determining if a load change is detected.

18. The method of claim 17 , wherein the load change is indicated in by a change in the duty cycle measured at the primary assembly.

19. The method of claim 1 , wherein controlling power transfer between the primary assembly and secondary assembly includes changing the power mode by an operation of a variable transformer on the primary assembly side.

20. The method of claim 1 , wherein controlling power transfer between the primary assembly and secondary assembly includes changing the power mode by varying input power with subharmonics of drive frequency.

21. The method of claim 20 , wherein the input power has a plurality of subharmonic states each corresponding to one of the scalable power modes.

22. The method of claim 1 , wherein controlling the power transfer between the primary assembly and secondary assembly includes changing the power mode by an operation of a variable voltage regulator on the primary assembly side.

23. The method of claim 22 wherein the variable voltage regulator has a plurality of discrete states each corresponding to one of the scalable power modes.

24. The method of claim 1 , wherein controlling the power transfer between the primary assembly and secondary assembly includes changing the power mode by an operation of a phase shifted bridge controller on the primary assembly side.

25. The method of claim 24 wherein the phase shifted bridge controller is configured for a plurality of phase shifts each corresponding to one of the scalable power modes.

Assignments (9)
RELEASE OF PATENT SECURITY AGREEMENT - REEL/FRAME 054795/0607, SUPPLEMENTAL PATENT SECURITY AGREEMENT - REAL/FRAME 056240/0147 AND ASSIGNMENT ID: 885388 Recorded Oct 1, 2025
From: TEXAS CAPITAL BANK, AS AGENT
To: MINNETRONIX MEDICAL, INC.
Reel/Frame 073434/0838 →
SECURITY INTEREST Recorded Sep 30, 2025
From: INTRICON CORPORATION; MINNETRONIX, INC.
To: CAPITAL ONE, NATIONAL ASSOCIATION, AS AGENT
Reel/Frame 072428/0878 →
ASSIGNMENT OF SECURITY INTEREST IN PATENT COLLATERAL RECORDED ON REEL 054795 FRAME 0607 AND SUPPLEMENTAL PATENT SECURITY AGREEMENT RECORDED ON REEL 056240 FRAME 0147 Recorded Mar 13, 2025
From: FIRST HORIZON BANK
To: TEXAS CAPITAL BANK, AS SUCCESSOR AGENT
Reel/Frame 073460/0969 →
SECURITY INTEREST Recorded Jan 4, 2021
From: MINNETRONIX MEDICAL, INC.; MINNETRONIX NEURO, INC.
To: FIRST HORIZON BANK, AS ADMINISTRATIVE AGENT
Reel/Frame 054795/0607 →
RELEASE OF SECURITY INTEREST Recorded Dec 31, 2020
From: MINNESOTA BANK & TRUST
To: MINNETRONIX MEDICAL, INC.; MINNETRONIX NEURO, INC.
Reel/Frame 054788/0122 →
SECURITY INTEREST Recorded Jul 11, 2019
From: MINNETRONIX MEDICAL, INC.
To: MINNESOTA BANK & TRUST
Reel/Frame 049727/0806 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2019
From: BLUVSHTEIN, VLAD; LUCKE, LORI
To: MINNETRONIX, INC.
Reel/Frame 049569/0926 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2019
From: WEISS, WILLIAM J.
To: THE PENN STATE RESEARCH FOUNDATION
Reel/Frame 048823/0121 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 25, 2016
From: BLUVSHTEIN, VLAD; LUCKE, LORI
To: MINNETRONIX, INC.
Reel/Frame 037574/0288 →